MOBERG DERMA RECEIVES APPROVAL TO INITIATE CLINICAL TRIAL FOR LIMTOP

MOBERG DERMA RECEIVES APPROVAL TO INITIATE CLINICAL TRIAL FOR LIMTOP

The German- Federal Institute for Drugs and Medical Devices (BfArM) has granted
Moberg Derma approval to initiate a clinical phase I trial for Limtop. Limtop is
an innovative formulation of an immunomodulatory compound with potential to
treat actinic keratosis, genital warts and basal cell carcinoma. The objective
is a product with short treatment duration, an improved safety profile and an
efficacy similar to or better than that of competing preparations. 

”Limtop has the potential to make a real difference for many patients who
currently suffer significant side effects, and we are now looking forward to
test the formulation clinically. The results from the Phase I study are expected
in the second quarter of 2012”, say Peter Wolpert, CEO and founder of Moberg
Derma.
About Limtop
Limtop is based on a patent-pending formulation of a proven compound that
results in an optimal dose of the active substance being delivered into the
skin. The company's preclinical results show that Limtop has a significantly
better capacity than existing preparations to transport the active substance to
the target tissue in the skin. Actinic keratosis is sun damage to the skin that
is characterised by thickening of the horny layer of the epidermis. The
condition has become more common as a result of changed lifestyle and increased
exposure to strong sunlight. Actinic keratosis can develop into squamous cell
carcinoma and should thus be treated. Prevalence varies, as fair-skinned
individuals are affected more. In populations in the northern hemisphere the
prevalence is reported as being between 11% and 25%. Over a million cases of
basal cell carcinoma are reported every year in the USA and the EU.

For further information, please contact:
Peter Wolpert, President and CEO
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35
E-mail: peter.wolpert@mobergderma.se
Magnus Persson, IR
Mobile: +46 73-355 26 01
E-mail: magnus.persson@mobergderma.se